INCY

SEC source: 0000879169-25-000091 · wk-form4_1752782690.xml · nonDerivative · entry 3

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,801

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

SEC source: 0000879169-25-000091 · wk-form4_1752782690.xml · nonDerivative · entry 2

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,504

SEC source: 0000879169-25-000091 · wk-form4_1752782690.xml · nonDerivative · entry 1

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,834

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000879169-25-000090 · wk-form4_1752782653.xml · derivative · entry 3

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,735

Underlying: Common Stock · 19,735 shares

Expires 2035-07-14

F4 · derivative.exercise_date: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000090 · wk-form4_1752782653.xml · derivative · entry 2

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,923

Underlying: Common Stock · 21,923 shares

Expires 2028-07-15

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

SEC source: 0000879169-25-000090 · wk-form4_1752782653.xml · nonDerivative · entry 1

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,252

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the July 15, 2025 grant, this includes an aggregate of 85,252 shares of common stock issuable pursuant to previously reported RSUs that have not vested.

SEC source: 0000879169-25-000088 · wk-form4_1752782572.xml · derivative · entry 1

Heeson Lee · CIK 0002039219 · EVP, Head of Incyte Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,577

Underlying: Common Stock · 6,577 shares

Expires 2028-07-15

F1 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F1 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

SEC source: 0000879169-25-000089 · wk-form4_1752782616.xml · derivative · entry 4

Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,841

Underlying: Common Stock · 11,841 shares

Expires 2035-07-14

F5 · derivative.exercise_date: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000089 · wk-form4_1752782616.xml · derivative · entry 3

Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,154

Underlying: Common Stock · 13,154 shares

Expires 2028-07-15

F4 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F4 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

SEC source: 0000879169-25-000089 · wk-form4_1752782616.xml · nonDerivative · entry 2

Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,016

F2 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F3 · balance_after: Including the July 15, 2025 grant, this includes an aggregate of 13,117 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-25-000089 · wk-form4_1752782616.xml · nonDerivative · entry 1

Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,755

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

SEC source: 0000879169-25-000087 · wk-form4_1752782534.xml · derivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,961

Underlying: Common Stock · 10,961 shares

Expires 2028-07-15

F1 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F1 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

SEC source: 0000879169-25-000086 · wk-form4_1752696353.xml · nonDerivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,890

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

SEC source: 0000879169-25-000085 · wk-form4_1752696308.xml · nonDerivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,911

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-25-000085 · wk-form4_1752696308.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,466

SEC source: 0000879169-25-000083 · wk-form4_1752696234.xml · nonDerivative · entry 1

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,097

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-25-000084 · wk-form4_1752696274.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,615

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-25-000082 · wk-form4_1752696197.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,414

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

SEC source: 0000879169-25-000081 · wk-form4_1752696159.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,106

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-25-000080 · wk-form4_1752696123.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,822

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-25-000079 · wk-form4_1752696081.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Special Advisor to the CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 521,859

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-25-000074 · wk-form4_1751921143.xml · nonDerivative · entry 2

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,744

F2 · balance_after: This includes an aggregate of 39,731 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-25-000072 · wk-form4_1751921008.xml · nonDerivative · entry 3

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,701

F2 · balance_after: Includes an aggregate of 34,913 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-25-000072 · wk-form4_1751921008.xml · nonDerivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,636

SEC source: 0000879169-25-000067 · wk-form4_1751488808.xml · derivative · entry 3

Meury William · CIK 0001536778 · Director · Chief Executive Officer · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2031-07-02

F4 · derivative.exercise_price: Each performance share represents the right to receive up to 400% of one share of common stock. The number of shares that may be earned and vested is contingent on the achievement of pre-established performance and vesting conditions over a six-year performance period, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2025.

F4 · derivative.exercise_date: Each performance share represents the right to receive up to 400% of one share of common stock. The number of shares that may be earned and vested is contingent on the achievement of pre-established performance and vesting conditions over a six-year performance period, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2025.

SEC source: 0000879169-25-000067 · wk-form4_1751488808.xml · derivative · entry 2

Meury William · CIK 0001536778 · Director · Chief Executive Officer · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,303

Underlying: Common Stock · 108,303 shares

Expires 2028-07-02

F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

SEC source: 0000879169-25-000067 · wk-form4_1751488808.xml · nonDerivative · entry 1

Meury William · CIK 0001536778 · Director · Chief Executive Officer · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,101

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes the July 2, 2025 aggregate grant of 36,101 shares of common stock.

SEC source: 0000879169-25-000078 · wk-form4_1751921772.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,059

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 34,329 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-25-000077 · wk-form4_1751921331.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,106

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 13,456 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-25-000075 · wk-form4_1751921217.xml · nonDerivative · entry 1

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,504

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 59,103 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-25-000076 · wk-form4_1751921297.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,418

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 94,907 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.

SEC source: 0000879169-25-000074 · wk-form4_1751921143.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,647

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-25-000073 · wk-form4_1751921075.xml · derivative · entry 3

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,158

Underlying: Common Stock · 599 shares

Expires 2033-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Beginning October 2, 2023, options become exercisable in 37 installments, with the first 25% vesting on October 2, 2024 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000073 · wk-form4_1751921075.xml · nonDerivative · entry 2

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,504

F1 · balance_after: This includes an aggregate of 25,848 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.

SEC source: 0000879169-25-000073 · wk-form4_1751921075.xml · nonDerivative · entry 1

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000879169-25-000072 · wk-form4_1751921008.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,318

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

SEC source: 0000879169-25-000071 · wk-form4_1751920928.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Special Advisor to the CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 526,820

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 94,538 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000950170-25-093244 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,187,581

F1 · shares: Includes 492 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $33,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 13,476 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 12,204 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,518 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 492 RSUs on Table I. The 492 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-093244 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,816,902

F1 · shares: Includes 492 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $33,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 13,476 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 12,204 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,518 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 492 RSUs on Table I. The 492 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000879169-25-000070 · wk-form4_1751489113.xml · nonDerivative · entry 1

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,950

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-25-000069 · wk-form4_1751489017.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,319

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-25-000068 · wk-form4_1751488914.xml · nonDerivative · entry 1

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,483

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years from the vesting commencement date of January 6, 2025. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the June 30, 2025 grant, this includes an aggregate of 76,483 shares of common stock issuable pursuant to previously reported RSUs that have not vested.

SEC source: 0001628280-25-033558 · wk-form4_1751323704.xml · derivative · entry 1

Meury William · CIK 0001536778 · Director · Chief Executive Officer · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,630

Underlying: Common Stock · 110,630 shares

Expires 2035-06-25

F1 · derivative.exercise_date: The June 26, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001628280-25-033513 · wk-form4_1751315517.xml · derivative · entry 3

Hoppenot Herve · CIK 0001596492 · Director · Special Advisor to the CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,050

Underlying: Common Stock · 18,050 shares

Expires 2028-06-26

F4 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ('TSR') over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date.

F4 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ('TSR') over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date.

SEC source: 0001628280-25-033513 · wk-form4_1751315517.xml · derivative · entry 2

Hoppenot Herve · CIK 0001596492 · Director · Special Advisor to the CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,438

Underlying: Common Stock · 18,438 shares

Expires 2035-06-25

F3 · derivative.exercise_date: The June 26, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0001628280-25-033513 · wk-form4_1751315517.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Special Advisor to the CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 569,589

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the June 26, 2025 grant, this includes an aggregate of 187,611 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0001628280-25-031014 · wk-form4_1749760266.xml · derivative · entry 2

BRAWLEY OTIS W · CIK 0001213029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0001628280-25-031014 · wk-form4_1749760266.xml · nonDerivative · entry 1

BRAWLEY OTIS W · CIK 0001213029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,252

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001628280-25-031009 · wk-form4_1749760200.xml · derivative · entry 2

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,216

Underlying: Common Stock · 9,216 shares

Expires 2035-06-09

F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

SEC source: 0001628280-25-031009 · wk-form4_1749760200.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,841

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.